According to a newly published market research report by 24LifeSciences, the global Galectin-3 inhibitor market was valued at USD 1.45 billion in 2025 and is projected to reach USD 2.91 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.1% during the forecast period 2026–2032. Galectin-3 inhibitors represent a novel class of therapeutic agents that target the galectin-3...